Carbon Dioxide Laser Surgery in Gynecology 

  • Author: Janice L Bacon, MD; Chief Editor: David Chelmow, MD   more...
 
Updated: May 9, 2011
 

History of the Procedure

The key mechanisms of action of the laser were first discovered by Albert Einstein in the early 1900s. Initial results from the use of a carbon dioxide laser for the management of cervical dysplasia were initially less successful than anticipated because of the inability to determine appropriate depth of penetration for prevention of recurrent disease. Not until 1978 did Anderson and Hartley emphasize the actual mechanics for the depth of cervical involvement.[1] Laser technique was further refined and shown to be both practical and efficacious by Jordan in 1985[2] and by Dorsey in 1979[3] , when the Greater Baltimore Medical Center published the first clinical experience with cervical conizations by carbon dioxide laser. See the image below.

Cervix after laser conization. Cervix after laser conization.

Lasers have provided the laparoscopic surgeon with an efficient method of achieving rapid excision, coagulation, or vaporization of pelvic abnormalities. Most familiar is therapy for pelvic endometriosis or adhesions. When laser is used in combination with other laparoscopic instruments, the variety of procedures performed with the laparoscope may be enhanced.

The carbon dioxide laser has been considered an effective modality for multiple tasks related to the treatment of intraepithelial neoplasia of the lower genital tract, most commonly for large lesions and for multifocal manifestations of human papilloma virus (HPV). The use of this technology is limited in some areas because of healthcare provider training and experience and because of a lack of availability of equipment. Many hospitals require that specific credentials be obtained before using this modality, including documentation of didactic instruction and clinical supervision of initial procedures.

Next

Problem

Intraepithelial neoplasia is a descriptive histologic term for squamous abnormalities of the vulva (VIN) and perianal area, vagina (VAIN) and cervix (CIN) (see the images below). Each site designation is subdivided into type 1 (mild), 2 (moderate), or 3 (severe dysplasia). Types 1, 2, and 3 correlate with the penetration of cellular abnormalities from the basement membrane to the surface. One third penetration is mild, two thirds penetration is moderate, and full thickness penetration is severe. Full thickness involvement by squamous abnormalities may also be designated carcinoma in situ based on nuclear and cytoplasmic evaluation.

White lesion is cervical intraepithelial neoplasm,White lesion is cervical intraepithelial neoplasm, grade I (CIN I). Cervical intraepithelial neoplasia, grades I and ICervical intraepithelial neoplasia, grades I and II (CIN I and II). Vulvar intraepithelial neoplasia, grade I (VIN I).Vulvar intraepithelial neoplasia, grade I (VIN I).

Pelvic pain related to adhesions or endometrial implants also represents a significant disease burden in the United States. Adhesions may be filmy or dense and may involve any pelvic structures. Endometrial implants may be clear or cystic, red or brown/black. Customarily, the older lesions are more darkly colored and accompanied by an increased depth of involvement with contracture of surrounding peritoneum or tissue surfaces. As the severity of endometriosis increases, the presence and severity of adhesions may also increase and become more dense. Visual evaluation of endometriosis may not completely correlate with depth of invasion of implants or with the patient's clinical symptoms.

The precision of the carbon dioxide laser delivered laparoscopically lends itself to intra-abdominal and intrapelvic adhesiolysis or ablation of endometrial implants.

Previous
Next

Epidemiology

Frequency

Worldwide prevalence of human papillomavirus infection is estimated to be 9-13%, involving 630 million infected individuals.[4, 5]

In 2005, the US Centers for Disease Control and Prevention estimated that 20 million Americans are DNA positive for anogenital types of human papillomavirus at any time. Almost one half of sexually active adolescents or young adults aged 15-24 years may be infected by the human papillomavirus. In the United States, 6.2 million individuals are estimated to become newly infected with human papillomavirus annually.

Previous
Next

Etiology

The most likely etiology of lower genital tract squamous abnormalities is infection with HPV, a double-stranded DNA virus of the Papovaviridae family. The HPV has more than 100 subtypes and is present in more than 90% of preinvasive and invasive squamous neoplasms of the cervix. Serotypes associated with squamous lesions may be designated as having a high or low risk for progression to malignancy. Research is being conducted to determine which serotypes may be more likely to produce high-grade lesions of the cervix, vagina, or vulva. Ultimate cure of the viral infection can only be achieved by the immune system of the human host.

Papillomaviruses are ubiquitous in higher vertebrates. Approximately 25 types of HPV infect the genital tract. Higher risk types, including types 16 and 18, are classified as such because of the gene products that bind to tumor suppressor portions of the host cells and cause their ultimate inactivation. Interactions of HPV with histocompatibility antigens may help explain why the same HPV type leads to invasive disease in one patient and not in another.[6]

Treatment modalities, such as the carbon dioxide laser, destroy or excise infected cells, thus reducing the amount of infected tissue and, presumably, the host viral load. The subsequent healing process of the host stimulates viral combat at the surgical site. Patients with abnormal cytology findings or visible lesions must first be evaluated with visual inspection using a colposcope to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when dysplasia is present or malignancy is considered, in the clinical opinion of the healthcare provider. Findings from one or more biopsy samples from the involved areas help document the location and histologic severity of the disease.

The carbon dioxide laser has been used for ablating high-grade lesions or excising abnormal areas, including the transformation zone of the cervix. Ablation may frequently be used for treating VIN and is also considered to be a treatment modality for VAIN requiring therapy.

In the pelvis, endometriosis has been hypothesized to be a result of endometrial cells producing disease in areas outside of the uterus, most likely by retrograde menstrual flow via patent fallopian tubes, but also potentially via vascular or lymphatic channels. Altered immune function within the peritoneal cavity, plus other potential factors, then permit development of endometrial implants, most frequently on the ovaries or in the cul-de-sac. Other sites in the abdomen or pelvis or remote sites may become involved.

Within the pelvis, the CO2 laser can be used to ablate affected sites or excise the peritoneum, thus improving anatomic relationships by lysing adhesions and excising endometrial implants.

When used in the pelvis for therapy of adhesions of other etiologies (eg, postoperative or postinfectious), the CO2 laser allows precise incision of the adhesions, restoring local anatomy with a primary goal of reduced, repeat adhesion formation and decreased risk of damage to adjacent structures.

Previous
Next

Indications

The carbon dioxide laser is customarily chosen over other ablative or excisional techniques when great precision is needed, particularly in situations involving large surface areas or when precise control over the depth of penetration is desired. Examples of procedures for which the carbon dioxide laser is indicated include (1) ablation or excision of dysplasia in situations in which minimization of tissue destruction or removal is desired; (2) cervical treatment combined with treatment of dysplasia or condylomata of the vulva, vaginal, perineal, or perirectal areas; (3) multifocal disease of the cervix, vagina, or vulva/perianal areas; (4) ablation or excision of endometrial implants or affected peritoneum; and (5) lysis of intra-abdominal or intrapelvic adhesions.

The carbon dioxide laser is used in conjunction with a laparoscope or colposcope. This allows precise application, which is one advantage of this treatment modality. Another advantage of the laser is hemostasis and minimal thermal necrosis (< 100 µm) when properly set. In addition, the procedure time is brief, and the laser may be used in an office or outpatient setting with the patient under local anesthesia when treating the vulva, vagina, or cervix. The office setting may also be more economical than procedures performed in a surgical suite. Surgical advantages of the intra-abdominal CO2 laser include (1) rapid incision and vaporization, (2) safety and predictability, and (3) lack of contact with the organ.

Patients with abnormal cervical cytology findings must first be evaluated using a colposcopy to help determine the location, extent, and severity of the clinical abnormalities. Colposcopically directed biopsies are indicated when the health care provider has determined dysplasia is present. Findings from 1 or more biopsy sample from the involved areas and findings from an endocervical curettage help document the location and histologic severity of the disease present.

The carbon dioxide laser has been used for ablating CIN or excising abnormal areas, including the cervical transformation zone.

Patients with visible lesions of the vagina, grossly compatible with HPV-related disorders, may be inspected with the colposcope and biopsy performed if the provider suspects dysplasia or to exclude malignancy.

Visible lesions of the vulva or perineum and perianal areas may indicate a need for biopsy to evaluate dysplasia, exclude malignancy, or further elucidate dermatologic disorders. The colposcope with or without acetic acid to the vulva may be invaluable in determining the presence or extent of disease while providing focused light in the area of interest.

The CO2 laser may be used whenever a diagnostic laparoscopic procedure can combine a diagnosis of disease and the extent of disease with immediate therapy. It may also be used to augment pain management associated with endometriotic implants via partial excision of the peritoneum or through laser destruction of the medial aspect of the uterosacral ligaments, interrupting nerve ending associated with central pelvic pain.

Previous
Next

Contraindications

Contraindications to using the carbon dioxide laser for the treatment of lower genital tract disease include (1) an inability to visualize the area to be treated because of anatomic considerations (eg, prolapsing lateral vaginal sidewall), (2) preoperative histology findings indicative of malignancy, and (3) inadequate physician training or experience. Laser ablation is contraindicated if the entire lesion is not visible, although excisional procedures may be performed.

Contraindications to laparoscopic use of the CO2 laser include (1) inability to visualize the site to be treated without risk of damage to adjacent structures, (2) anatomic findings not consistent with the diagnosis of endometriosis or adhesions (eg, neoplasm), (3) inadequate physician training or experience.

Previous
Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Janice L Bacon, MD  Professor and Chair, Department of Obstetrics and Gynecology, University of South Carolina School of Medicine

Janice L Bacon, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics, Association of Reproductive Health Professionals, North American Society for Pediatric and Adolescent Gynecology, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Karen Loeb Lifford, MD  Director of General Gynecology, Associate Program Director, Department of Obstetrics and Gynecology, Instructor, Brigham and Women's Hospital, Harvard Medical School

Karen Loeb Lifford, MD is a member of the following medical societies: Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Frederick B Gaupp, MD  Consulting Staff, Department of Family Practice, Hancock Medical Center

Frederick B Gaupp, MD is a member of the following medical societies: American Academy of Family Physicians

Disclosure: Nothing to disclose.

Chief Editor

David Chelmow, MD  Leo J Dunn Distinguished Professor and Chair, Department of Obstetrics and Gynecology, Virginia Commonwealth University Medical Center

David Chelmow, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Phi Beta Kappa, Sigma Xi, Society for Gynecologic Investigation, and Society for Medical Decision Making

Disclosure: Nothing to disclose.

References
  1. Anderson MC, Hartley RB. Cervical crypt involvement by intraepithelial neoplasia. Obstet Gynecol. May 1980;55(5):546-50. [Medline].

  2. Jordan JA, Woodman CB, Mylotte MJ, et al. The treatment of cervical intraepithelial neoplasia by laser vaporization. Br J Obstet Gynaecol. Apr 1985;92(4):394-8. [Medline].

  3. Dorsey JH, Diggs ES. Microsurgical conization of the cervix by carbon dioxide laser. Obstet Gynecol. Nov 1979;54(5):565-70. [Medline].

  4. American Cancer Society Atlanta, GA. Cancer Facts and Figures 2006. American Cancer Society. 2006;4.

  5. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. Apr 1 2009;124(7):1626-36. [Medline].

  6. Lungu O, Sun XW, Felix J, et al. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA. May 13 1992;267(18):2493-6. [Medline].

  7. Agency for Healthcare Policy and Research. Evaluation of Cervical Cytology. Evidence Report/Technology Assessment No. 5. AHCPR Publication No. 99-E010. Bethesda, Md: Bethesda, Md: Agency for Healthcare Policy and Research; February 1999.; February 1999.

  8. Wright TC, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Lower Genital Tract Dis. 2007;11:201-222.

  9. Wisniewski PM, Warhol MJ, Rando RF, Sedlacek TV, Kemp JE, Fisher JC. Studies on the transmission of viral disease via the CO2 laser plume and ejecta. J Reprod Med. Dec 1990;35(12):1117-23. [Medline].

  10. Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume emissions after papovavirus irradiation with the carbon dioxide laser. J Reprod Med. May 1982;27(5):268-70. [Medline].

  11. OSHA. Laser/Electrosurgery Plume. United States Department of Labor, Occupational Safety & Health Administration. Available at http://www.osha.gov/SLTC/laserelectrosurgeryplume/index.html. Accessed March 10, 2009.

  12. Dorsey JH. Laser surgery for cervical intraepithelial neoplasia. In: Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders Company; 1991:475-489.

  13. Reid R. Physical and surgical principles of laser surgery in the lower genital tract. In: Chohan N, Barron HA, eds. Obstetrics and Gynecology Clinics of North America. Philadelphia, Pa: WB Saunders and Company; 1991:429-74.

  14. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol. Dec 2008;112(6):1419-44. [Medline].

  15. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. Nov 1998;92(5):737-44. [Medline].

  16. Gardeil F, Barry-Walsh C, Prendiville W, Clinch J, Turner MJ. Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. Obstet Gynecol. Mar 1997;89(3):419-22. [Medline].

  17. Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol. Sep 2002;86(3):365-9. [Medline].

  18. Mathevet P, Dargent D, Roy M, Beau G. A randomized prospective study comparing three techniques of conization: cold knife, laser, and LEEP. Gynecol Oncol. Aug 1994;54(2):175-9. [Medline].

  19. Spitzer M. Vaginal estrogen administration to prevent cervical os obliteration following cervical conization in women with amenorrhea. J Lower Genital Tract Dis. 1997;1:53.

  20. Sadler L, Saftlas A. Cervical surgery and preterm birth. Journal of Perintal Medicine. 2007;35:5-9. [Medline].

  21. Sjoborg KD, Vistad I, Myhr SS, Svenningsen R, Herzog C, Kloster-Jensen A, et al. Pregnancy outcome after cervical cone excision: a case-control study. Act Obstetricia et Gynecologica Scandinavica. 2007;86:423-428. [Medline].

  22. Jancar N, Rakar S, Poljak M, Fujs K, Kocjan BJ, Vrtacnik-Bokal E. Efficacy of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. Eur J Gynaec Oncol. 2006;27:239-242. [Medline].

  23. Schafer A, Friedmann W, Mielke M, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol. Feb 1991;164(2):593-9. [Medline].

  24. Tate DR, Anderson RJ. Recurrence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. Am J Obstet Gynecol. May 2002;186(5):880-2. [Medline].

  25. Maiman M, Fruchter RG, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol. Aug 1993;82(2):170-4. [Medline].

  26. Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol. Mar 1996;87(3):338-44. [Medline].

  27. Kjellberg L, Wadell G, Bergman F, et al. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol. Nov 2000;183(5):1238-42. [Medline].

  28. Solomon D, Schiffman M, Tarone R, et al. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. Feb 21 2001;93(4):293-9. [Medline].

  29. Bar-Am A, Daniel Y, Ron IG, et al. Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervial dysplasia. Gynecol Oncol. 2000;78:47-51. [Medline].

  30. dos Santos L, Odunsi K, Lele S. Clinicopathologic outcomes of laser conization for high-grade cervical dysplasia. Eur J Gynaecol Oncol. 2004;25(3):305-7. [Medline].

  31. Klobucar A, Hrgovic Z, Bukovic D, et al. The treatment of cervical dysplasia with laser. Med Arh. 2004;58(6):355-7. [Medline].

  32. Mitchell MF, Tortolero-Luna G, Wright T, Sarkar A, Richards-Kortum R, Hong WK. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr. 1996;(21):17-25. [Medline].

  33. Ueda M, Ueki K, Kanemura M, Izuma S, Yamaguchi H, Nishiyama K, et al. Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. Gynecologic Oncology. April 2006;101:143-146. [Medline].

  34. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. Mar 1 2005;191(5):731-8. [Medline].

Previous
Next
 
White lesion is cervical intraepithelial neoplasm, grade I (CIN I).
Cervical intraepithelial neoplasia, grades I and II (CIN I and II).
Cervix after laser conization.
Vulvar intraepithelial neoplasia, grade I (VIN I).
Table. The 4 Surgical Planes in Laser Surgery of the Vulva*
Parameter First Second Third Fourth
TissueSurface epitheliumDermal papillaePilosebaceous ductsPilosebaceous glands
Vaporization zoneProliferating layer of epidermisPapillary dermis (superficial)Upper reticular dermisMid-reticular dermis
Necrosis ZoneBasement membraneDeep papillary dermisMidreticular dermisDeep reticular dermis
HealingRapid/nonscarringRapid/nonscarringSlower/usually nonscarringSkin grafting required
Landmarks visualizedPink surface after removing charYellow, nonreflectiveWhite, fibrous arcuate vessels seenSkin appendages visible
*Adapted from Obstetrics and Gynecology Clinics of North America, Lasers in Gynecology[13]
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.